Literature DB >> 6105559

Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis.

A S Gastanaduy, E L Kaplan, B B Huwe, C McKay, L W Wannamaker.   

Abstract

In an outbreak of group A streptococcal pharyngitis in a semi-closed community, 42 (25%) of 169 courses of antibiotic therapy failed to eradicate the organism. 16 (19%) of 85 individuals treated with intramuscular benzathine penicillin G and 9 (19%) of 47 patients treated with an oral antibiotic (penicillin V or erythromycin) continued to harbour the same serotype of group A streptococcus. 12 (48%) of 25 persons remained treatment failures after re-treatment; even after a third course of treatment 5 of 12 (42%) still harboured the organism. Neither antibiotic resistance of the epidemic strain nor reacquisition of the organism from contacts could be implicated as causes. The data suggest that many who did not respond to treatment were streptococcal carriers and raise the possibility that it is more difficult to eradicate the organism from the carrier than from the acutely infected individual.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105559     DOI: 10.1016/s0140-6736(80)91832-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

1.  Prophylactic efficiency of 3-weekly benzathine penicillin G in rheumatic fever.

Authors:  B Oran; A Tastekin; S Karaaslan; L Bas; A Ayçiçek; A Ceri; A Sütçü; I Erkul
Journal:  Indian J Pediatr       Date:  2000-03       Impact factor: 1.967

2.  Azithromycin versus Penicillin in Acute Group A Streptococcal Tonsillopharyngitis.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

3.  In vivo lysogenic conversion of Tox(-) Streptococcus pyogenes to Tox(+) with Lysogenic Streptococci or free phage.

Authors:  Thomas B Broudy; Vincent A Fischetti
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

4.  Molecular DNA analysis for differentiation of persistence or relapse from recurrence in treatment failure of Streptococcus pyogenes pharyngitis.

Authors:  F Fitoussi; R Cohen; G Brami; C Doit; N Brahimi; F de la Rocque; E Bingen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

Review 5.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

6.  Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Pharyngitis Study Group.

Authors:  D Adam; H Scholz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

7.  The extended microbiology of group A streptococcal pharyngitis. Observations during a double-blind controlled study of cephalexin twice versus four-times daily.

Authors:  M M Tarpay; S Chartrand; M Marks; A Cox
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

8.  Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis.

Authors:  J Cremer; C Wallrauch; D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis.

Authors:  D Milatovic; D Adam; H Hamilton; E Materman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

10.  Evaluation of bacterial interference and beta-lactamase production in management of experimental infection with group A beta-hemolytic streptococci.

Authors:  I Brook; J D Gilmore
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.